DEVELOP HERE.
BUILD SUPPLY HERE.

Map starting-material dependencies, identify U.S. synthesis and analytical capabilities, and evaluate qualified contract development and manufacturing organizations. The objective is traceable, quality-controlled material rather than dependence on research-product resellers.

Recruit U.S.-based scientific leadership and qualify domestic laboratories for analytical, pharmacology, exposure and initial safety work. Develop the regulatory plan and candidate specifications with appropriate specialists.

Military and civilian critical workers share an interest in dependable medical supply. FDA’s domestic-manufacturing initiatives establish current policy relevance. They do not grant Antaeus approval, funding, participation or an accelerated pathway.

No U.S. API manufacturing contract, CDMO appointment, laboratory agreement or government partnership is represented as secured. Initial financing supports supplier qualification and a preclinical candidate decision. Commercial GMP manufacturing requires subsequent development and capital.

Seek a funded study or development collaboration around heat-associated exertional fatigue. Evaluate active SBIR/STTR calls against eligibility and fit. Procurement and field deployment follow the evidence and regulatory pathway.